A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation

Antonio E. Muruato, Camila R. Fontes-Garfias, Ping Ren, Mariano A. Garcia-Blanco, Vineet D. Menachery, Xuping Xie () and Pei-Yong Shi ()
Additional contact information
Antonio E. Muruato: University of Texas Medical Branch
Camila R. Fontes-Garfias: University of Texas Medical Branch
Ping Ren: University of Texas Medical Branch
Mariano A. Garcia-Blanco: University of Texas Medical Branch
Vineet D. Menachery: University of Texas Medical Branch
Xuping Xie: University of Texas Medical Branch
Pei-Yong Shi: University of Texas Medical Branch

Nature Communications, 2020, vol. 11, issue 1, 1-6

Abstract: Abstract Virus neutralization remains the gold standard for determining antibody efficacy. Therefore, a high-throughput assay to measure SARS-CoV-2 neutralizing antibodies is urgently needed for COVID-19 serodiagnosis, convalescent plasma therapy, and vaccine development. Here, we report on a fluorescence-based SARS-CoV-2 neutralization assay that detects SARS-CoV-2 neutralizing antibodies in COVID-19 patient specimens and yields comparable results to plaque reduction neutralizing assay, the gold standard of serological testing. The fluorescence-based neutralization assay is specific to measure COVID-19 neutralizing antibodies without cross reacting with patient specimens with other viral, bacterial, or parasitic infections. Collectively, our approach offers a rapid platform that can be scaled to screen people for antibody protection from COVID-19, a key parameter necessary to safely reopen local communities.

Date: 2020
References: Add references at CitEc
Citations: View citations in EconPapers (4)

Downloads: (external link)
https://www.nature.com/articles/s41467-020-17892-0 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-17892-0

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-020-17892-0

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().